Sam Altman on ChatGPT’s First Two Years, Elon Musk and AI Under Trump
AlexNet, created by Alex Krizhevsky, Sutskever and Geoffrey Hinton, used a deep convolutional neural network (CNN)—a powerful new type of computer program—to recognize images far more accurately than ever, kick-starting major progress in AI.
Oklo (OKLO) is a clean energy producer that aims to use advanced fission power plants to generate clean and affordable energy ...
As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals ...
Immediately following his brief firing from OpenAI, Altman considered starting another AI company, something Chesky and Conway helped talk him out of.
6don MSN
Sam Altman's OpenAI is backing a new AI initiative from a group where John Kerry was a founding member that has voiced ...
And now, after years of stasis in Silicon Valley, we have Sam Altman ... product of unusual self-awareness. Altman, famously, was in the "first class" of Y Combinator, Silicon Valley's ur ...
Sam Altman says the most important piece of advice he’s ever received came from Paul Graham, who last year hand-picked Altman to take over as head of his Y Combinator, the acclaimed startup ...
OpenAI CEO Sam Altman sat before Congress in 2023 to testify ... While Altman's investment through Y Combinator was known, his investment through Sequoia was not. OpenAI discloses Altman's ...
2024 The New York Times Company Sam Altman is the co-founder and C.E.O ... Altman was president of the early-stage start-up accelerator Y Combinator from 2014 to 2019. In 2015, Altman ...
Sam Altman, founding partner and president of Y Combinator, one of the most coveted startup accelerators in the country, has been outspoken this year about his disdain for the rate at which ...
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback